The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Updates from the DETERMINATION trial: RVD vs. autoSCT in patients with multiple myeloma
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the DETERMINATION trial (NCT01208662) evaluating the use of lenalidomide, bortezomib, and dexamethasone versus high-dose treatment with autologous stem cell transplantation (autoSCT) in patients with multiple myeloma. Dr Richardson first highlights some results from this trial, including the progression-free survival (PFS) observed in patients and the importance of transplant in controlling event-free survival (EFS). Dr Richardson then discusses the toxicities observed and further highlights other therapies changing the myeloma treatment landscape, including quadruplet therapies, monoclonal antibodies, CAR-T therapy, and bispecific T-cell engagers (BiTEs). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
